Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) have been assigned a consensus recommendation of “Reduce” from the six research firms that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $4.16.
DNA has been the subject of a number of recent research reports. TD Cowen boosted their target price on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, September 20th. The Goldman Sachs Group decreased their target price on shares of Ginkgo Bioworks from $0.80 to $0.30 and set a “sell” rating for the company in a research report on Tuesday, July 9th. Finally, BTIG Research lifted their price target on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a “sell” rating in a report on Friday, August 23rd.
Read Our Latest Stock Report on Ginkgo Bioworks
Institutional Inflows and Outflows
Ginkgo Bioworks Stock Performance
NYSE:DNA opened at $8.89 on Friday. The firm has a 50-day simple moving average of $7.37. Ginkgo Bioworks has a one year low of $5.26 and a one year high of $75.20. The company has a market cap of $19.65 billion, a price-to-earnings ratio of -20.19 and a beta of 1.10.
Ginkgo Bioworks (NYSE:DNA – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($3.20) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($3.20). The business had revenue of $56.21 million for the quarter, compared to analysts’ expectations of $41.46 million. Ginkgo Bioworks had a negative return on equity of 63.09% and a negative net margin of 486.98%. Sell-side analysts expect that Ginkgo Bioworks will post -12.6 EPS for the current fiscal year.
About Ginkgo Bioworks
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
- Five stocks we like better than Ginkgo Bioworks
- What to Know About Investing in Penny Stocks
- Survey Reveals: America’s Most Coveted Businesses in 2024
- What Are the FAANG Stocks and Are They Good Investments?
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- How to Plot Fibonacci Price Inflection Levels
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.